PT  - JOURNAL ARTICLE
AU  - Abdallah, Chadi G.
TI  - Brain Networks Associated With COVID-19 Risk: Data From 3,662 Participants
AID  - 10.1101/2021.04.01.21254709
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.01.21254709
4099  - http://medrxiv.org/content/early/2021/12/08/2021.04.01.21254709.short
4100  - http://medrxiv.org/content/early/2021/12/08/2021.04.01.21254709.full
AB  - Background Our behavioral traits, and subsequent actions, could affect the risk of exposure to the coronavirus disease of 2019 (COVID-19). The current study aimed to determine whether unique brain networks are associated with the COVID-19 infection risk.Methods This research was conducted using the UK Biobank Resource. Functional magnetic resonance imaging scans in a cohort of general population (n=3,662) were used to compute the whole-brain functional connectomes. A network-informed machine learning approach was used to identify connectome and nodal fingerprints that are associated with positive COVID-19 status during the pandemic up to February 4th, 2021.Results The predictive models successfully identified 6 fingerprints that were associated with COVID-19 positive, compared to negative status (all p values < 0.005). Overall, lower integration across the brain modules and increased segregation, as reflected by internal within module connectivity, were associated with higher infection rates. More specifically, COVID-19 positive status was associated with 1) reduced connectivity between the central executive and ventral salience, as well as between the dorsal salience and default mode networks; 2) increased internal connectivity within the default mode, ventral salience, subcortical and sensorimotor networks; and 3) increased connectivity between the ventral salience, subcortical and sensorimotor networks.Conclusion Individuals are at increased risk of COVID-19 infections if their brain connectome is consistent with reduced connectivity in the top-down attention and executive networks, along with increased internal connectivity in the introspective and instinctive networks. These identified risk networks could be investigated as target for treatment of illnesses with impulse control deficits.Competing Interest StatementDr. Abdallah has served as a consultant, speaker and/or on advisory boards for Genentech, Janssen, Psilocybin Labs, Lundbeck, Guidepoint, and FSV7, and as editor of Chronic Stress for Sage Publications, Inc. He also filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (Aug 20, 2018).Funding StatementThis work was supported by the Department of Veterans Affairs, the VA National Center for PTSD and the Beth K and Stuart Yudofsky Chair in the Neuropsychiatry of Military Post Traumatic Stress Syndrome. The funding sources have had no involvement in the study design, the analysis and interpretation of data, the writing of this report, or the decision to submit this article for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in this study were extracted from the UK Biobank data repository under application number 42826. All study procedures were approved by the UK Biobank Institutional Review Boards and all participants completed an informed consent process.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are publicly available through the UK Biobank. https://bbams.ndph.ox.ac.uk/ams/